Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of histamine dihydrochloride on immunological biomarkers and minimal residual disease in patients with acute myeloid leukaemia in first remission.

Next Previous
Search
Trial Profile

Effects of histamine dihydrochloride on immunological biomarkers and minimal residual disease in patients with acute myeloid leukaemia in first remission.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Histamine dihydrochloride (Primary) ; Interleukin-2
  • Indications Acute myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms RE:MISSION
  • Sponsors Immune Pharmaceuticals Inc

    • Most Recent Events

    • 19 Apr 2016 Biomarker data presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, according to an Immune Pharmaceuticals Inc media release.
    • 12 Jan 2016 Results of this study in a biomarker-defined sub-population are expected in 2016, as per Immune Pharmaceuticals media release.
    • 25 Feb 2011 Results from this trial will be used to refine the EU labeling for Histamine-dihydrochloride [Ceplene].

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top